Gilead Acquires PepStar’s HCXT-2001 for $1.3B: What Does It Mean for Market Access?
Summary Gilead Sciences has agreed to acquire HCXT-2001. The experimental immune disease drug comes from Shanghai-based PepStar Therapeutics. The cash deal is valued at close to $1.3 billion. HCXT-2001 is